Targeted cancer therapy pioneer John Mendelsohn, M.D., researcher and former president of The University of Texas MD Anderson Cancer Center, will share the 2018 Tang Prize in Biopharmaceutical Science for his leadership in developing antibodies to block cancer-promoting growth factor receptors on the surface of cancer cells.
In announcing the award on June 19 in Taiwan, the Tang Foundation noted the three awardees launched the...
A study led by The University of Texas MD Anderson Cancer Center revealed that the investigational drug quizartinib prolonged overall survival...
Using a targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint inhibitors...
Researchers at Houston Methodist Research Institute and The University of Texas MD Anderson Cancer Center have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer.
Their preclinical research, reported in the Journal of the National Cancer Institute, integrated computational modeling...
The University of Texas MD Anderson Cancer Center will host its 20th annual Making Cancer History® seminar in Aspen, 10 a.m.-12 p.m. Monday...
In a randomized, Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center adding the PARP inhibitor veliparib...
A drug discovered and advanced by The University of Texas MD Anderson Cancer Center’s Institute for Applied Cancer Science (IACS) and TRACTION...
Recognizing that vaccination rates for the human papillomavirus (HPV) remain low across the U.S., particularly in Texas, The University of...
The University of Texas MD Anderson Cancer Center has named eight researchers to the third annual class of Andrew Sabin Family Fellows. As...
Clinical trials show that an immune checkpoint inhibitor shrinks the tumors of nearly half of patients with an incurable, advanced form of...